share_log

Cantor Fitzgerald Reiterates Overweight on Alpha Tau Medical, Maintains $23 Price Target

Cantor Fitzgerald Reiterates Overweight on Alpha Tau Medical, Maintains $23 Price Target

坎托·菲茨杰拉德重申增持 Alpha Tau Medical,维持23美元的目标股价
Benzinga ·  2023/08/29 10:24

Cantor Fitzgerald analyst Kristen Kluska reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Overweight and maintains $23 price target.

Cantor Fitzgerald分析师Kristen Kluska重申Alpha Tau Medical(纳斯达克:DRTS)增持,并维持23美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发